>The remaining defects are rare and generally transmitted as autosomal recessive disorders, with prevalences ranging from approximately 1 in 500,000 to 1 in 2 million<
Monday’s CC gave the actual number of individuals in the indication that GTC and LFB plan to pursue—severe hemophilia with inhibitors: 21,000 in the U.S. and 36,000 in Europe. This works out to about 1 case in every 7,000 males.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”